Expressed by the Epithelial cells of the prostate, PSA (a Protease) rises secondary to any combination of Prostatitis,
Benign Prostatic Hyperplasia (BPH) and Prostate Cancer.
In a male aged 45 years, it would not be uncommon for the PSA to be elevated secondary to Prostatitis & Prostate
Enlargement. If the PSA is greater than 0.7 ng/ml, this man has a 3-4 times increased incidence of Prostate Cancer when
compared to a male with a PSA less than 0.7 ng/ml. (Reference: Johns Hopkins' White Paper,
March - 2002).
The Peenuts® Prostate Formula has been shown in clinical trials to decrease the PSA by greater than 50% with regular
usage.
An elevated PSA is commonly interpreted by traditionalists as Prostate
Cancer, despite the fact that only 20-30% of biopsies reflect cancer
Although you have herd that a PSA of 0-4 ng/ml is normal, IT IS NOT
NORMAL!; 20-30% of all Prostate Cancers are in the 0-4 range, making this a true medical oxymoron. Be wary when you
are told your PSA is "normal"-GET TO KNOW THE NUMBER AND DON’T TAKE A NEEDLESS RISK!
Peenuts, in a Prospective Prostate Cancer Study, demonstrated a reduction in EPS of 77.5% which resulted in a decrease
in PSA of 58%; Translation-all men with Prostate Cancer should be on Peenuts
PSA is not altered by Saw Palmetto (Marks & Gerber)
The most common cause of an elevated PSA is Prostatitis, although the
most common fear is Prostate Cancer
All patients with known Prostatitis on PEENUTS® improved their PSA
(N=154)
The PSA level improved by an average of 50%
Range of improvement of PSA (.3 - 35.6)
As the PSA drops, the risk of Prostate Cancer decreased in all
patients on PEENUTS® by reproducible biological markers
Health of the prostate improved in all patients on PEENUTS® secondary
to an improvement in PSA, "The Barometer of Prostate Health"
Range of age of patients noting improvement in PSA on PEENUTS® 19 - 86
year olds
Expectation is that PSA increases with age; on PEENUTS®, PSA decreases
in all ages
Most dramatic improvement of patients on PEENUTS®: PSA 43 - 7.4
Patient PSA Data (Private Practice
Subset)
Intitials
PSA
F/U
PSA
%
Change
Time to
surveillance
Comments
S.S
16.6
11.3
32%
37 mo
Biopsy Negative x 2
m.s
14.9
6.7
55%
6 mo
Biopsy Negative
D.J.
33.9
5.7
83%
6 mo
Biopsy Negative
D.L.
5.6
1.8
68%
14 mo
HGPIN
D.S.
7
2.6
63%
14 mo
HGPIN (Biopsy x 3)
B.L.
5.8
4.9
16%
1 mo
Prostate Cancer (PC)
R.L.
5.3
4.9
8%
4 mo
PC
S.K.
4.2
1.6
62%
12 mo
PC
R.P.
8.4
2.9
65%
13 mo
PC
F.W.
8.5
3.1
64%
72 mo.
PC; + Avodart®
J.B.
7
2.4
66%
60 mo.
PC
S.A.
4.7
2.1
55%
41 mo.
PC; + Avodart®
J.W.
11.7
5.8
50%
60 mo.
PC
R.C
2.9
1.7
41%
72 mo.
PC
J.C.
2.1
2.8
33%(+)
42 mo.
PC; + Avodart®
W.G.
7.3
4.5
38%
40 mo.
PC; + Avodart®
R.V.
6.9
6
13%
38 mo.
PC
D.S.
9.1
5.5
40%
58 mo.
PC
J.G.
3.2
2
38%
21 mo.
PC; + Avodart®
G.D.
6.2
4.4
29%
21 mo
PC
C.B.
4.4
1.7
61%
39 mo.
PC; + Avodart®
J.S.
11.4
12.3
8%(+)
34 mo.
PC
L.R.
6.8
1.9
72%
49 mo
PC; + Avodart®
E.E.
6.6
1.8
73%
24 mo.
PC
J.M.
14.4
1.5
90%
29 mo.
PC; + Avodart®
J.C.
8.4
1.8
79%
18 mo.
PC; + Avodart®
R.W.
4.4
4.7
.7%(+)
14 mo
PC; + Avodart®
R.C.
6.1
1.3
79%
13 mo.
PC
R.W.
0.5
0.3
40%
84 mo.
A.C.
3.6
1.4
61%
4.5 mo.
B.R.
1.2
0.58
52%
6 mo.
R.A.
0.9
0.7
22%
6 mo.
C.B.
6.9
5.8
16%
6 mo.
L.A.
3.4
2.7
21%
6 mo.
P.R.
3.9
3
23%
6 mo.
B.D.
9.26
8.44
9%
3 mo.
R.C.
7 4
6
34%
19 mo.
N.F.
6.8
2.5
63%
16 mo.
S.G.
3.5
2.6
26%
12 mo.
R.G.
4.4
4.9
11%(+)
9 mo.
R.H.
9.1
3.36
63%
27 mo.
G.H.
13
9.6
26%
2 mo.
F.H.
6.5
3.9
40%
12 mo.
S.H.
1.16
0.92
21%
12 mo.
R.H.
13
11.4
12%
7 mo.
D.H.
5.8
4.7
19%
2 mo.
D.J.
13.8
5.23
62%
4 mo.
D.G.
3.3
0.97
71%
26 mo.
E.L.
7.6
4.3
43%
47 mo.
B.M.
0.6
0.4
33%
41 mo.
K.M.
4.8
1.9
60%
15 mo.
J.M.
11.79
6.7
43%
24 mo.
E.M.
10.6
8.8
17%
8 mo.
W.M.
0.7
0.7
0%
25 mo.
W.M.
3.8
2
47%
48 mo.
R.M.
6.3
4.4
30%
22 mo.
C.M.
3.7
1.6
57%
24 mo.
R.M.
6.6
3.2
46%
39 mo.
R.S.
1.64
0.9
45%
4 mo.
R.N.
2.89
1.77
39%
7 mo.
R.N.
5.8
2.43
58%
32 mo.
F.R.
10.8
5.2
52%
6 mo.
J.R.
9.84
4.3
56%
12 mo.
F.R.
5.2
3.1
40%
6 mo.
J.R.
7.1
2.8
61%
44 mo.
W.S.
2.4
1.6
33%
56 mo.
D.S.
11.7
3.7
68%
19 mo.
M.W.
7.1
5.6
21%
8 mo.
T.M.
7.7
3.8
51%
48 mo.
Biopsy Negative
S.G
0.6
0.6
0%
42 mo.
J.K.
5.4
2.6
48%
48 mo.
D.S.
9.8
3.7
62%
15 mo.
Plus Avodart®
R.E.
24.1
9.2
62%
9 mo.
Bx.X(2)(Neg); Plus Avodart®
L.W.
6.4
0.7
89%
T.G.
43
7.4
83%
4 mo.
R.D.
16
3.8
76%
11 mo.
R.V.
2.9
2.1
28%
B.C.
2.1
0.9
57%
B.M.
7.9
7
11%
H.M.
11.4
4.1
64%
10 mo.
C.A.
14
2.7
81%
J.S.
8.4
4.2
50%
8 mo.
M.S.
3.8
0.8
79%
R.V.
25
16
36%
9 mo.
Biopsy Negative X 2
G.S.
6.8
4.7
31%
G.M.
8.8
5.4
39%
D.E.
25.3
3
88%
8 mo.
Biopsy Negative
C.R.
4.7
3.7
21%
B.G.
2.5
2.1
16%
C.P.
4.1
2.8
32%
V.J.
4.5
3.6
20%
L.V.
15.6
5.4
65%
D.V.
3.8
1.2
68%
J.C.
10
3.1
69%
C.C.
22
19
14%
H.F.
5.3
4.6
13%
F.J.
7.5
5.2
31%
R.H.
8.5
5.4
37%
R.A.
2.5
2.2
12%
R.G.
5.9
5.5
7%
G.T.
1.4
0.8
43%
6 mo.
G.H.
36
1.6
96%
V.S.
3.8
2.9
24%
C.C.
5.6
4.3
23%
R.L.
7.4
4.1
45%
C.D.
3.6
2.4
33%
J.L.
4.0
3.5
13%
4 mo.
L.G.
1.3
0.9
31%
12 mo.
R.S.
11.0
5.8
47%
4 mo.
E.L.
6.7
4.2
37%
3.5 mo.
M.L.
11.4
7.4
35%
3 mo.
C.T.
2.6
2.0
23%
5 mo.
L.S.
4.1
3.4
17%
10 mo.
E.S.
4.3
3.2
26%
6 mo.
J.B.
4.6
3.9
15%
9 mo.
B.D.
9.3
4.8
48%
5 mo.
M.S.
7.5
5.4
28%
9 mo.
R.N.
7.0
2.1
69%
8 mo.
E.G.
4.7
4.1
13%
3 mo.
L.L.
2.6
1.3
50%
13 mo.
D.L.
18.0
10.5
42%
4 mo.
Negative Biopsy X 2
H.K.
5.6
2.6
54%
6 mo.
P.H.
1.0
0.9
10%
6 mo.
A.A.
4.5
0.8
82%
9 mo.
C.C.
5.9
3.7
37%
14 mo.
J.A.
7.5
4.9
35%
2 mo.
R.A.
0.8
0.5
38%
10 mo.
E.H.
0.9
0.6
33%
20 mo.
R.D.
13.6
7.2
47%
2 mo.
E.H.
1.5
1.2
20%
12 mo.
T.M.
8.1
1.7
79%
2 mo.
R.K.
25
16
36%
L.T.
6.8
4.7
31%
A.B.
8.8
5.4
39%
D.M.
3.8
0.8
79%
A.S.
2.9
2.1
28%
L.M.
8.4
4.2
50%
C.B.
14
2.7
81%
K.T.
11.4
4.1
64%
S.R.
7.9
7.0
11%
I.B.
25.3
3.0
88%
S.W.
4.7
3.7
21%
C.F.
2.5
2.1
16%
E.C.
4.5
3.6
20%
B.R.
4.1
2.8
32%
S.H.
15.6
5.4
65%
R.R.
3.8
1.2
68%
T.S.
10
3.1
69%
J.D.
22
19
14%
C.L.
5.3
4.6
13%
A.L.
7.5
5.2
31%
A.R.
8.5
5.4
37%
M.M.
2.5
2.2
12%
N.S.
5.9
5.5
7%
N=154 Mean 7.8 Mean 3.9 Mean50%
Preferred
Health Resources
1819 Main St. Suite 240 Sarasota, Florida 34236
Phone: (941) 951-2415 Toll Free: (888) PEENUTS (733-6887)
Patented herbal prostate nutrition - physician tested and approved
